1997: 1199

EBMT ACTIVITY SURVEY 2017

Helen Baldomero, Jakob Passweg

Activiy Survey Office - University Hospital Basel, Switzerland

Activity Survey 2017

Patient and Transplant Numbers

Teams : 683	Participating countries: 50		
	Allogeneic	Autologous	Total
1st. allo / 1st. auto HSCT	**17 155**	**23 945**	**41 100**
Re/Additional transplants	1 126	3 192	4 318
Total HSCT	**18 281**	**27 137**	**45 418**
Myeloablative HSCT	**61%**		
Main Indications 1st. HSCT			
Myeloid malignancies	9 772	375	10 147
Lymphoid malignancies	5 015	21 473	26 488
Solid tumours	36	1 571	1 607
Bone marrow failure	802	1	803
Other non-malignant disorders	1 371	493	1 864
Other	159	32	191
Myeloid malignancies			
AML 1st. CR	3 753	293	4 046
not 1st. CR	1 950	59	2 009
AML therapy related	277	2	279
AML from MDS/MPN	696	6	702
CML 1st. cP	136	0	136
not 1st. cP	199	0	199
MDS or MD/MPN, MPN	2 761	15	2 776
Lymphoid neoplasia			
ALL 1st. CR	1 652	82	1 734
not 1st. CR	1 029	8	1 037
CLL	230	9	239
Plasma cell disorders	385	12 692	13 077
Hodgkin lymphoma	444	2 152	2 596
Non-Hodgkin lymphoma	1 275	6 530	7 805
Solid tumours			
Neuroblastoma	26	537	563
Soft tissue sarcoma/Ewing	8	229	237
Germ cell tumour	0	372	372
Breast cancer	0	13	13
Other solid tumour	2	420	422
Non malignant disorders			
Bone marrow failure - SAA	583	1	584
Bone marrow failure - other	219	0	219
Thalassemia	420	6	426
Sickle cell disease	215	1	216
Primary immune deficiency	554	13	567
Inherited disorder of metabolism	159	10	169
Auto immune disorder	23	463	486
Others	159	32	191

Paediatric patients													
Family								Unrelated			Autologous		
HLA-id/twin			Haplo-id		Other relative								
BM	PB	CB	BM	PB	BM	PB	CB	BM	PB	CB	BM	PB	CB
930	283	31	183	471	89	89	2	893	588	166	80	1 249	2
2 078								1 647			1 331		

Other trends in 2017

- Number of HSCT continue to increase: > 45, 400 HSCT
- Continued increase in haplo-identical HSCT: 13%
- Continued decrease in cord blood HSCT: 16%
- Continued increase in cellular therapies: 28% since 2015

Epub: JR. Passweg, H. Baldomero et al, Bone Marrow Transplantation, 6. Feb 2019. Contact: helen.baldomero@usb.ch

HSCT in Europe 2017

Figure 1a: Allogeneic HSCT



Proportion of allogeneic HSCT over time	2017	2007	1997
AML	38.9	32.5	24.5
CML	2.0	4.3	25.3
MDS/MPN	16.1	13.4	6.8
ALL	15.6	17.7	20.0
CLL	1.3	3.2	0.7
PCD	2.2	5.0	3.2
HL	2.6	2.8	0.7
NHL	7.4	8.5	4.8
Solid tumour	0.2	0.6	0.3
BMF	4.7	5.2	5.0
Hemogl.	3.7	2.5	2.6
PID	3.2	2.7	1.7
IDM	0.9	0.8	2.8
AID	0.1	0.1	0.1
Others	0.9	0.7	1.6
	100	100	100

Figure 1b: Autologous HSCT



Proportion of autologous HSCT over time	2017	2007	1997
Myeloid disorders	1.6	4.5	9.2
ALL/CLL	0.4	1.3	3.8
PCD	53.0	42.0	18.3
HL	9.0	11.8	8.7
NHL	27.3	29.9	25.1
Pediatric solid tumors	3.2	4.2	5.2
Germ cell tumors	1.6	1.9	4.3
Breast cancer	0.1	0.6	21.5
Other solid tumors	1.8	2.5	3.0
NMD	0.1	0.1	0
AID	1.9	1.0	0.2
Others	0.1	0.1	0.7
	100	100	100

Figure 1:shows the distribution of disease indications for allogeneic (a) and autologous (b) HSCT. For comparative analyses, the 2017 data (100%) are juxtaposed to the analogous data from the years 2007 and 1997.

Allo HSCT: has increased 3.6-fold from 4,751 to 17,155 over 20 years. CML has declined from 25.3% to 2%, AML, MDS and MPN have increased. ALL has decreased slightly while other lymphoid malignancies have increased.

Auto HSCT: has increased 2-fold from 12,199 to 23,945 over 20 years. Myeloma is the dominant indication increasing from 18% to 53%. HL and NHL have remained stable. AML has decreased from 13% to 1.72%. Solid tumour HSCT has decreased, predominantly in breast cancer.

Figure 2: Allogeneic HSCT for non-malignant disorders in Europe 1990-2017



Since 2016:

increase seen in sickle cell disease by 57%, thalassemia by 28% and IHD by 6%.

BMF decreased by 10.3%.

Non HSCT Cellular therapies using manipulated or selected cells in 2017

Number of patients	MSC		NK cells		select/exp T cells or CIK		Reg T cells (TREGS)		Genetic mod. T cells		Dendritic cells		Expanded CD34+ cells		Genetic mod. CD34+ cells		Other	
	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto	Allo	Auto
GvHD	413	5			8		36										13	
Graft enhancement	55	18	1		14		5		57			4	6		1		44	8
AID	6	14	19										1					21
Genetic disease	1															13		
Infection	3				113												8	
Malignancy			6		42		24	8	16	78	5	35	2				32	5
Regenerative med.	31	11	1		2								2				4	11
Total	**509**	**48**	**27**		**179**		**65**	**8**	**73**	**78**	**5**	**39**	**11**		**1**	**13**	**101**	**45**